{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:26:31Z","timestamp":1793139991244,"version":"4.5.0"},"reference-count":131,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Appetite"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.appet.2026.108723","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:35:28Z","timestamp":1784853328000},"page":"108723","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["One receptor, two opposite approaches: efficacy and tolerability of GIPR agonism and antagonism in obesity pharmacotherapy"],"prefix":"10.1016","volume":"227","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-6438-9192","authenticated-orcid":false,"given":"Serena X.","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9438-695X","authenticated-orcid":false,"given":"Tito","family":"Borner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.appet.2026.108723_bib1","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/s42255-025-01299-6","article-title":"Unravelling the GIPR agonist versus antagonist paradox","volume":"7","author":"Adriaenssens","year":"2025","journal-title":"Nature Metabolism"},{"issue":"5","key":"10.1016\/j.appet.2026.108723_bib2","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.cmet.2019.07.013","article-title":"Glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus regulate food intake","volume":"30","author":"Adriaenssens","year":"2019","journal-title":"Cell Metabolism"},{"issue":"10","key":"10.1016\/j.appet.2026.108723_bib3","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.164921","article-title":"Hypothalamic and brainstem glucose-dependent insulinotropic polypeptide receptor neurons employ distinct mechanisms to affect feeding","volume":"8","author":"Adriaenssens","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.appet.2026.108723_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2024.101915","article-title":"Loss of GIPR in LEPR cells impairs glucose control by GIP and GIP:GLP-1 co-agonism without affecting body weight and food intake in mice","volume":"83","author":"Akindehin","year":"2024","journal-title":"Molecular Metabolism"},{"issue":"9","key":"10.1016\/j.appet.2026.108723_bib5","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1038\/npp.2014.74","article-title":"Glucagon-like Peptide-1 receptor signaling in the lateral parabrachial nucleus contributes to the control of food intake and motivation to feed","volume":"39","author":"Alhadeff","year":"2014","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.appet.2026.108723_bib6","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1210\/en.2011-1443","article-title":"GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake","volume":"153","author":"Alhadeff","year":"2012","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.appet.2026.108723_bib7","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1016\/j.appet.2026.108723_bib8","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.2337\/db17-0480","article-title":"The Gluco- and liporegulatory and vasodilatory effects of glucose-dependent insulinotropic Polypeptide (GIP) are abolished by an antagonist of the human GIP receptor","volume":"66","author":"Asmar","year":"2017","journal-title":"Diabetes"},{"issue":"9","key":"10.1016\/j.appet.2026.108723_bib9","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.2337\/db10-0098","article-title":"Glucose-dependent insulinotropic polypeptide may enhance fatty acid re-esterification in subcutaneous abdominal adipose tissue in lean humans","volume":"59","author":"Asmar","year":"2010","journal-title":"Diabetes"},{"issue":"11","key":"10.1016\/j.appet.2026.108723_bib10","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1001\/jamasurg.2025.3590","article-title":"Obesity treatment with bariatric surgery vs GLP-1 receptor agonists","volume":"160","author":"Barrett","year":"2025","journal-title":"JAMA Surgery"},{"issue":"3","key":"10.1016\/j.appet.2026.108723_bib11","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/dom.12824","article-title":"Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials","volume":"19","author":"Bettge","year":"2017","journal-title":"Diabetes, Obesity and Metabolism"},{"issue":"4","key":"10.1016\/j.appet.2026.108723_bib12","doi-asserted-by":"crossref","first-page":"E835","DOI":"10.1152\/ajpendo.00646.2020","article-title":"GIP receptor deletion in mice confers resistance to high-fat diet-induced obesity via alterations in energy expenditure and adipose tissue lipid metabolism","volume":"320","author":"Boer","year":"2021","journal-title":"American Journal of Physiology. Endocrinology and Metabolism"},{"issue":"4","key":"10.1016\/j.appet.2026.108723_bib13","doi-asserted-by":"crossref","first-page":"E528","DOI":"10.1152\/ajpendo.00330.2023","article-title":"The antiemetic actions of GIP receptor agonism","volume":"326","author":"Borner","year":"2024","journal-title":"American Journal of Physiology-Endocrinology and Metabolism"},{"issue":"11","key":"10.1016\/j.appet.2026.108723_bib14","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.2337\/db21-0459","article-title":"GIP receptor agonism attenuates GLP-1 receptor agonist\u2013induced nausea and emesis in preclinical models","volume":"70","author":"Borner","year":"2021","journal-title":"Diabetes"},{"key":"10.1016\/j.appet.2026.108723_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2026.102334","article-title":"GIPR signaling modulates PYY-induced hypophagia and malaise in rodents","volume":"106","author":"Borner","year":"2026","journal-title":"Molecular Metabolism"},{"issue":"25","key":"10.1016\/j.appet.2026.108723_bib16","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adu1589","article-title":"Hypophagia and body weight loss by tirzepatide are accompanied by fewer GI adverse events compared to semaglutide in preclinical models","volume":"11","author":"Borner","year":"2025","journal-title":"Science Advances"},{"key":"10.1016\/j.appet.2026.108723_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2023.101743","article-title":"GIP receptor agonism blocks chemotherapy-induced nausea and vomiting","volume":"73","author":"Borner","year":"2023","journal-title":"Molecular Metabolism"},{"issue":"4","key":"10.1016\/j.appet.2026.108723_bib18","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/bph.15647","article-title":"Glucagon-like peptide-1 in diabetes care: Can glycaemic control be achieved without nausea and vomiting?","volume":"179","author":"Borner","year":"2022","journal-title":"British Journal of Pharmacology"},{"issue":"59","key":"10.1016\/j.appet.2026.108723_bib19","article-title":"Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms","volume":"46","author":"Campbell","year":"2021","journal-title":"Molecular Metabolism, Emerging Therapeutics for Diabetes, Obesity, and Related Complications"},{"issue":"8","key":"10.1016\/j.appet.2026.108723_bib20","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.2337\/db25-0393","article-title":"Therapeutic targeting of the GIP receptor\u2014revisiting the controversies","volume":"74","author":"Campbell","year":"2025","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.appet.2026.108723_bib21","doi-asserted-by":"crossref","DOI":"10.1096\/fj.201903253R","article-title":"Glucose-dependent insulinotropic polypeptide modifies adipose plasticity and promotes beige adipogenesis of human omental adipose-derived stem cells","volume":"35","author":"Chen","year":"2021","journal-title":"FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology"},{"key":"10.1016\/j.appet.2026.108723_bib22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Molecular Metabolism"},{"key":"10.1016\/j.appet.2026.108723_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101407","article-title":"Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation","volume":"55","author":"Costa","year":"2022","journal-title":"Molecular Metabolism"},{"key":"10.1016\/j.appet.2026.108723_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2025.102094","article-title":"Chronic GIPR agonism results in pancreatic islet GIPR functional desensitisation","volume":"92","author":"Davies","year":"2025","journal-title":"Molecular Metabolism"},{"issue":"8","key":"10.1016\/j.appet.2026.108723_bib25","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s42255-025-01342-6","article-title":"Fluorescent GLP1R\/GIPR dual agonist probes reveal cell targets in the pancreas and brain","volume":"7","author":"de Bray","year":"2025","journal-title":"Nature Metabolism"},{"key":"10.1016\/j.appet.2026.108723_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g2646","article-title":"Long term maintenance of weight loss with non-surgical interventions in obese adults: Systematic review and meta-analyses of randomised controlled trials","volume":"348","author":"Dombrowski","year":"2014","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.appet.2026.108723_bib27","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.2337\/diab.28.12.1141","article-title":"Gastric inhibitory polypeptide enhanced lipoprotein lipase activity in cultured preadipocytes","volume":"28","author":"Eckel","year":"1979","journal-title":"Diabetes"},{"key":"10.1016\/j.appet.2026.108723_bib28","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.molmet.2018.03.016","article-title":"Profiling of G protein-coupled receptors in vagal afferents reveals novel gut-to-brain sensing mechanisms","volume":"12","author":"Egerod","year":"2018","journal-title":"Molecular Metabolism"},{"key":"10.1016\/j.appet.2026.108723_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2025.102214","article-title":"Downstream interaction by glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonism is required for synergistic effects on body weight","volume":"99","author":"Feetham","year":"2025","journal-title":"Molecular Metabolism"},{"issue":"209","key":"10.1016\/j.appet.2026.108723_bib30","doi-asserted-by":"crossref","first-page":"209ra151","DOI":"10.1126\/scitranslmed.3007218","article-title":"Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans","volume":"5","author":"Finan","year":"2013","journal-title":"Science Translational Medicine"},{"issue":"5","key":"10.1016\/j.appet.2026.108723_bib31","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.molmed.2016.03.005","article-title":"Reappraisal of GIP pharmacology for metabolic diseases","volume":"22","author":"Finan","year":"2016","journal-title":"Trends in Molecular Medicine"},{"issue":"2","key":"10.1016\/j.appet.2026.108723_bib32","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.cmet.2017.07.011","article-title":"The sustained effects of a dual GIP\/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes","volume":"26","author":"Frias","year":"2017","journal-title":"Cell Metabolism"},{"issue":"6","key":"10.1016\/j.appet.2026.108723_bib33","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Frias","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1016\/j.appet.2026.108723_bib34","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/dom.13979","volume":"22","author":"Frias","year":"2020","journal-title":"Diabetes, Obesity and Metabolism"},{"issue":"10160","key":"10.1016\/j.appet.2026.108723_bib35","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: A randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Frias","year":"2018","journal-title":"Lancet (London, England)"},{"issue":"7","key":"10.1016\/j.appet.2026.108723_bib36","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJMoa2502081","article-title":"Coadministered cagrilintide and semaglutide in adults with overweight or obesity","volume":"393","author":"Garvey","year":"2025","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1016\/j.appet.2026.108723_bib37","doi-asserted-by":"crossref","first-page":"906","DOI":"10.2337\/db18-1123","article-title":"Separate and combined glucometabolic effects of endogenous glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 in healthy individuals","volume":"68","author":"Gasbjerg","year":"2019","journal-title":"Diabetes"},{"issue":"14","key":"10.1016\/j.appet.2026.108723_bib38","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1111\/bph.16478","article-title":"Altered desensitization and internalization patterns of rodent versus human glucose-dependent insulinotropic polypeptide (GIP) receptors. An important drug discovery challenge","volume":"182","author":"Gasbjerg","year":"2025","journal-title":"British Journal of Pharmacology"},{"issue":"11","key":"10.1016\/j.appet.2026.108723_bib39","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1111\/dom.15216","article-title":"The importance of glucose\u2010dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide","volume":"25","author":"Gasbjerg","year":"2023","journal-title":"Diabetes, Obesity and Metabolism"},{"issue":"8","key":"10.1016\/j.appet.2026.108723_bib40","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.2337\/diabetes.54.8.2436","article-title":"Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes","volume":"54","author":"Gault","year":"2005","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.appet.2026.108723_bib41","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s00125-002-1028-x","article-title":"Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob\/ob) mice: Evidence that GIP is the major physiological incretin","volume":"46","author":"Gault","year":"2003","journal-title":"Diabetologia"},{"key":"10.1016\/j.appet.2026.108723_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.obpill.2024.100127","article-title":"Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks","volume":"12","author":"Ghusn","year":"2024","journal-title":"Obesity Pillars"},{"issue":"3","key":"10.1016\/j.appet.2026.108723_bib43","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.cmet.2012.06.015","article-title":"Hindbrain neurons as an essential hub in the neuroanatomically distributed control of energy balance","volume":"16","author":"Grill","year":"2012","journal-title":"Cell Metabolism"},{"issue":"6","key":"10.1016\/j.appet.2026.108723_bib44","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1038\/s42255-025-01294-x","article-title":"GIPR agonism and antagonism decrease body weight and food intake via different mechanisms in male mice","volume":"7","author":"Gutgesell","year":"2025","journal-title":"Nature Metabolism"},{"issue":"9","key":"10.1016\/j.appet.2026.108723_bib45","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1016\/j.cmet.2025.07.009","article-title":"Glucose-dependent insulinotropic polypeptide receptor signaling in oligodendrocytes increases the weight-loss action of GLP-1R agonism","volume":"37","author":"Hansford","year":"2025","journal-title":"Cell Metabolism"},{"issue":"5\u20136","key":"10.1016\/j.appet.2026.108723_bib46","first-page":"282","article-title":"Effects of gastric inhibitory polypeptide on glucose and lipid metabolism of isolated rat adipocytes","volume":"32","author":"Hauner","year":"2008","journal-title":"Annals of Nutrition and Metabolism"},{"issue":"6","key":"10.1016\/j.appet.2026.108723_bib47","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1210\/en.2008-1479","article-title":"Endogenous hindbrain glucagon-like peptide-1 receptor activation contributes to the control of food intake by mediating gastric satiation signaling","volume":"150","author":"Hayes","year":"2009","journal-title":"Endocrinology"},{"issue":"7","key":"10.1016\/j.appet.2026.108723_bib48","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1038\/oby.2011.50","article-title":"Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats","volume":"19","author":"Hayes","year":"2011","journal-title":"Obesity (Silver Spring, Md"},{"issue":"12","key":"10.1016\/j.appet.2026.108723_bib49","doi-asserted-by":"crossref","first-page":"7211","DOI":"10.1038\/s41380-021-01220-z","article-title":"5-HT recruits distinct neurocircuits to inhibit hunger-driven and non-hunger-driven feeding","volume":"26","author":"He","year":"2021","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.appet.2026.108723_bib50","author":"Heimburger"},{"issue":"6","key":"10.1016\/j.appet.2026.108723_bib51","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S2213-8587(22)00085-7","article-title":"Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: A multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial","volume":"10","author":"Heise","year":"2022","journal-title":"The Lancet Diabetes & Endocrinology"},{"issue":"23","key":"10.1016\/j.appet.2026.108723_bib52","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra0706547","article-title":"Chemotherapy-induced nausea and vomiting","volume":"358","author":"Hesketh","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"8025","key":"10.1016\/j.appet.2026.108723_bib53","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41586-024-07685-6","article-title":"Dissociable hindbrain GLP1R circuits for satiety and aversion","volume":"632","author":"Huang","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.appet.2026.108723_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2019.170203","article-title":"Blockade of gastric inhibitory polypeptide (GIP) action as a novel means of countering insulin resistance in the treatment of obesity-diabetes","volume":"125","author":"Irwin","year":"2020","journal-title":"Peptides"},{"issue":"7","key":"10.1016\/j.appet.2026.108723_bib55","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1007\/s00125-007-0692-2","article-title":"Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob\/ob mice","volume":"50","author":"Irwin","year":"2007","journal-title":"Diabetologia"},{"issue":"10","key":"10.1016\/j.appet.2026.108723_bib56","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1038\/s41366-025-01859-6","article-title":"Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: A systematic review and network meta-analysis","volume":"49","author":"Ismaiel","year":"2025","journal-title":"International Journal of Obesity"},{"issue":"3","key":"10.1016\/j.appet.2026.108723_bib57","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.appet.2026.108723_bib58","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2504214","article-title":"Once-monthly maridebart cafraglutide for the treatment of obesity\u2014A phase 2 trial","author":"Jastreboff","year":"2025","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.appet.2026.108723_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2024.102006","article-title":"AT-7687, a novel GIPR peptide antagonist, combined with a GLP-1 agonist, leads to enhanced weight loss and metabolic improvements in cynomolgus monkeys","volume":"88","author":"Jensen","year":"2024","journal-title":"Molecular Metabolism"},{"issue":"1","key":"10.1016\/j.appet.2026.108723_bib60","doi-asserted-by":"crossref","first-page":"28","DOI":"10.7570\/jomes22012","article-title":"The upcoming weekly tides (Semaglutide vs. tirzepatide) against obesity: STEP or SURPASS?","volume":"31","author":"Jung","year":"2022","journal-title":"Journal of Obesity & Metabolic Syndrome"},{"issue":"5","key":"10.1016\/j.appet.2026.108723_bib61","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/j.neuropharm.2011.12.022","article-title":"The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide","volume":"62","author":"Kanoski","year":"2012","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.appet.2026.108723_bib62","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.bbrc.2014.07.116","article-title":"Endogenous GLP-1 acts on paraventricular nucleus to suppress feeding: Projection from nucleus tractus solitarius and activation of corticotropin-releasing hormone, nesfatin-1 and oxytocin neurons","volume":"451","author":"Katsurada","year":"2014","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"1","key":"10.1016\/j.appet.2026.108723_bib63","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.1038\/s41467-020-18751-8","article-title":"Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism","volume":"11","author":"Killion","year":"2020","journal-title":"Nature Communications"},{"issue":"472","key":"10.1016\/j.appet.2026.108723_bib64","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat3392","article-title":"Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models","volume":"10","author":"Killion","year":"2018","journal-title":"Science Translational Medicine"},{"issue":"12","key":"10.1016\/j.appet.2026.108723_bib65","doi-asserted-by":"crossref","first-page":"8557","DOI":"10.1074\/jbc.M609088200","article-title":"Activation of lipoprotein lipase by glucose-dependent insulinotropic polypeptide in adipocytes. A role for a protein kinase B, LKB1, and AMP-activated protein kinase cascade","volume":"282","author":"Kim","year":"2007","journal-title":"Journal of Biological Chemistry"},{"issue":"47","key":"10.1016\/j.appet.2026.108723_bib66","doi-asserted-by":"crossref","first-page":"34139","DOI":"10.1074\/jbc.M704896200","article-title":"Resistin is a key mediator of glucose-dependent insulinotropic polypeptide (GIP) stimulation of lipoprotein lipase (LPL) activity in adipocytes","volume":"282","author":"Kim","year":"2007","journal-title":"Journal of Biological Chemistry"},{"issue":"11","key":"10.1016\/j.appet.2026.108723_bib67","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1194\/jlr.M006841","article-title":"GIP increases human adipocyte LPL expression through CREB and TORC2-mediated trans-activation of the LPL gene","volume":"51","author":"Kim","year":"2010","journal-title":"Journal of Lipid Research"},{"issue":"7","key":"10.1016\/j.appet.2026.108723_bib68","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/s42255-024-01061-4","article-title":"Characterization of genetic variants of GIPR reveals a contribution of \u03b2-arrestin to metabolic phenotypes","volume":"6","author":"Kizilkaya","year":"2024","journal-title":"Nature Metabolism"},{"issue":"2","key":"10.1016\/j.appet.2026.108723_bib69","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/jn\/125.2.183","article-title":"Investigations into the actions of glucose-dependent insulinotropic polypeptide and glucagon-like Peptide-1(7\u201336)amide on lipoprotein lipase activity in explants of rat adipose tissue","volume":"125","author":"Knapper","year":"1995","journal-title":"The Journal of Nutrition"},{"issue":"11","key":"10.1016\/j.appet.2026.108723_bib70","doi-asserted-by":"crossref","first-page":"5474","DOI":"10.1111\/dom.15875","article-title":"A long-acting glucose-dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon-like peptide-1 receptor agonist therapy","volume":"26","author":"Knop","year":"2024","journal-title":"Diabetes, Obesity and Metabolism"},{"issue":"8","key":"10.1016\/j.appet.2026.108723_bib71","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1016\/j.celrep.2019.04.096","article-title":"An Atlas of vagal sensory neurons and their molecular specialization","volume":"27","author":"Kupari","year":"2019","journal-title":"Cell Reports"},{"issue":"15","key":"10.1016\/j.appet.2026.108723_bib72","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1016\/j.cell.2024.06.003","article-title":"Transforming obesity: The advancement of multi-receptor drugs","volume":"187","author":"Kusminski","year":"2024","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.appet.2026.108723_bib73","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.2337\/dc10-1255","article-title":"The public health implications of the cost-effectiveness of bariatric surgery for diabetes","volume":"33","author":"Laiteerapong","year":"2010","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.appet.2026.108723_bib74","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1258\/acb.2007.007068","article-title":"Supraphysiological doses of intravenous PYY3-36 cause nausea, but no additional reduction in food intake","volume":"45","author":"Le Roux","year":"2008","journal-title":"Annals of Clinical Biochemistry: International Journal of Laboratory Medicine"},{"key":"10.1016\/j.appet.2026.108723_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2024.101945","article-title":"Stimulating intestinal GIP release reduces food intake and body weight in mice","volume":"84","author":"Lewis","year":"2024","journal-title":"Molecular Metabolism"},{"issue":"12","key":"10.1016\/j.appet.2026.108723_bib76","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/s42255-023-00931-7","article-title":"Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice","volume":"5","author":"Liskiewicz","year":"2023","journal-title":"Nature Metabolism"},{"issue":"6","key":"10.1016\/j.appet.2026.108723_bib77","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1038\/s42255-025-01295-w","article-title":"GIPR-Ab\/GLP-1 peptide\u2013antibody conjugate requires brain GIPR and GLP-1R for additive weight loss in obese mice","volume":"7","author":"Liu","year":"2025","journal-title":"Nature Metabolism"},{"issue":"5","key":"10.1016\/j.appet.2026.108723_bib78","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/mp.2017.187","article-title":"Lateral hypothalamic GLP-1 receptors are critical for the control of food reinforcement, ingestive behavior and body weight","volume":"23","author":"L\u00f3pez-Ferreras","year":"2018","journal-title":"Molecular Psychiatry"},{"issue":"5","key":"10.1016\/j.appet.2026.108723_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2021.100263","article-title":"GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys","volume":"2","author":"Lu","year":"2021","journal-title":"Cell Reports Medicine"},{"issue":"4","key":"10.1016\/j.appet.2026.108723_bib80","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s42255-021-00363-1","article-title":"A genetic map of the mouse dorsal vagal complex and its role in obesity","volume":"3","author":"Ludwig","year":"2021","journal-title":"Nature Metabolism"},{"issue":"9","key":"10.1016\/j.appet.2026.108723_bib81","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.2337\/dbi21-0003","article-title":"Single-Cell mapping of GLP-1 and GIP receptor expression in the dorsal vagal complex","volume":"70","author":"Ludwig","year":"2021","journal-title":"Diabetes"},{"key":"10.1016\/j.appet.2026.108723_bib82","doi-asserted-by":"crossref","DOI":"10.1038\/s44319-025-00582-7","article-title":"Acute exogenous acyl-GIP treatment enhances lipid handling and fatty acid oxidation by involving brown fat","author":"Lyons","year":"2025","journal-title":"EMBO Reports"},{"issue":"12","key":"10.1016\/j.appet.2026.108723_bib83","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1210\/clinem\/dgae319","article-title":"Effects of tirzepatide vs semaglutide on \u03b2-Cell function, insulin sensitivity, and glucose control during a meal test","volume":"109","author":"Mather","year":"2024","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"issue":"6","key":"10.1016\/j.appet.2026.108723_bib84","doi-asserted-by":"crossref","first-page":"E1746","DOI":"10.1152\/ajpendo.00460.2007","article-title":"GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet","volume":"293","author":"McClean","year":"2007","journal-title":"American Journal of Physiology. Endocrinology and Metabolism"},{"issue":"1","key":"10.1016\/j.appet.2026.108723_bib85","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1210\/endo.140.1.6464","article-title":"Glucose-dependent insulinotropic polypeptide stimulation of lipolysis in differentiated 3T3-L1 cells: Wortmannin-sensitive inhibition by insulin","volume":"140","author":"McIntosh","year":"1999","journal-title":"Endocrinology"},{"issue":"7","key":"10.1016\/j.appet.2026.108723_bib86","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nm727","article-title":"Inhibition of gastric inhibitory polypeptide signaling prevents obesity","volume":"8","author":"Miyawaki","year":"2002","journal-title":"Nature Medicine"},{"key":"10.1016\/j.appet.2026.108723_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2025.102118","article-title":"Glucose-dependent insulinotropic polypeptide (GIP)","volume":"95","author":"M\u00fcller","year":"2025","journal-title":"Molecular Metabolism"},{"key":"10.1016\/j.appet.2026.108723_bib89","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Molecular Metabolism"},{"key":"10.1016\/j.appet.2026.108723_bib87","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.molmet.2018.12.001","article-title":"Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism","volume":"20","author":"Mroz","year":"2019","journal-title":"Molecular Metabolism"},{"issue":"1","key":"10.1016\/j.appet.2026.108723_bib90","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.autneu.2003.11.001","article-title":"Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells","volume":"110","author":"Nakagawa","year":"2004","journal-title":"Autonomic Neuroscience: Basic & Clinical"},{"issue":"2","key":"10.1016\/j.appet.2026.108723_bib91","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/osp4.164","article-title":"Gastric inhibitory polypeptide receptor antagonist, SKL-14959, suppressed body weight gain on diet-induced obesity mice","volume":"4","author":"Nakamura","year":"2018","journal-title":"Obesity Science & Practice"},{"issue":"1","key":"10.1016\/j.appet.2026.108723_bib92","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","article-title":"Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction","volume":"21","author":"Nauck","year":"2022","journal-title":"Cardiovascular Diabetology"},{"issue":"7","key":"10.1016\/j.appet.2026.108723_bib93","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1523\/JNEUROSCI.4920-04.2005","article-title":"Glucose-dependent insulinotropic polypeptide is expressed in adult hippocampus and induces progenitor cell proliferation","volume":"25","author":"Nyberg","year":"2005","journal-title":"Journal of Neuroscience: The Official Journal of the Society for Neuroscience"},{"issue":"10","key":"10.1016\/j.appet.2026.108723_bib94","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/jnr.21349","article-title":"Immunohistochemical distribution of glucose-dependent insulinotropic polypeptide in the adult rat brain","volume":"85","author":"Nyberg","year":"2007","journal-title":"Journal of Neuroscience Research"},{"issue":"3","key":"10.1016\/j.appet.2026.108723_bib95","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2174\/187152411798047771","article-title":"Gastric inhibitory polypeptide and its receptor are expressed in the central nervous system and support neuronal survival","volume":"11","author":"Paratore","year":"2011","journal-title":"Central Nervous System Agents in Medicinal Chemistry"},{"issue":"0","key":"10.1016\/j.appet.2026.108723_bib96","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.cmet.2024.05.010","article-title":"Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor","author":"Regmi","year":"2024","journal-title":"Cell Metabolism, 0"},{"issue":"4","key":"10.1016\/j.appet.2026.108723_bib97","doi-asserted-by":"crossref","DOI":"10.1080\/21688370.2023.2292461","article-title":"Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer's and Parkinson's diseases","volume":"12","author":"Rhea","year":"2024","journal-title":"Tissue Barriers"},{"issue":"3","key":"10.1016\/j.appet.2026.108723_bib98","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0119034","article-title":"Activation of the GLP-1 receptors in the nucleus of the solitary tract reduces food reward behavior and targets the mesolimbic system","volume":"10","author":"Richard","year":"2015","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.appet.2026.108723_bib99","doi-asserted-by":"crossref","first-page":"4356","DOI":"10.1210\/en.2014-1248","article-title":"GLP-1 receptor stimulation of the lateral parabrachial nucleus reduces food intake: Neuroanatomical, electrophysiological, and behavioral evidence","volume":"155","author":"Richard","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.appet.2026.108723_bib100","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11905","article-title":"Genetically and functionally defined NTS to PBN brain circuits mediating anorexia","volume":"7","author":"Roman","year":"2016","journal-title":"Nature Communications"},{"issue":"8","key":"10.1016\/j.appet.2026.108723_bib101","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.2337\/dbi24-0027","article-title":"GIP receptor antagonists in the pharmacotherapy of obesity: Physiologic, genetic, and clinical rationale","volume":"74","author":"Rosenkilde","year":"2025","journal-title":"Diabetes"},{"issue":"12","key":"10.1016\/j.appet.2026.108723_bib102","doi-asserted-by":"crossref","DOI":"10.1172\/JCI146353","article-title":"GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in Obese mice","volume":"131","author":"Samms","year":"2021","journal-title":"The Journal of Clinical Investigation"},{"issue":"7","key":"10.1016\/j.appet.2026.108723_bib103","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.2337\/db21-0848","article-title":"GIPR agonism inhibits PYY-induced nausea-like behavior","volume":"71","author":"Samms","year":"2022","journal-title":"Diabetes"},{"issue":"9","key":"10.1016\/j.appet.2026.108723_bib106","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.2337\/dbi21-0002","article-title":"GIPR function in the central nervous system: Implications and novel perspectives for GIP-Basedz therapies in treating metabolic disorders","volume":"70","author":"Samms","year":"2021","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.appet.2026.108723_bib104","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1146\/annurev-physiol-022724-105443","article-title":"A mechanistic rationale for incretin-based therapeutics in the management of obesity","volume":"87","author":"Samms","year":"2025","journal-title":"Annual Review of Physiology"},{"issue":"8","key":"10.1016\/j.appet.2026.108723_bib105","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.2337\/dbi24-0026","article-title":"A contemporary rationale for agonism of the GIP receptor in the treatment of obesity","volume":"74","author":"Samms","year":"2025","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.appet.2026.108723_bib107","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.14493","article-title":"Efficacy and safety of oral small molecule glucagon-like peptide 1 receptor agonist danuglipron for glycemic control among patients with type 2 diabetes: A randomized clinical trial","volume":"6","author":"Saxena","year":"2023","journal-title":"JAMA Network Open"},{"issue":"6","key":"10.1016\/j.appet.2026.108723_bib108","doi-asserted-by":"crossref","first-page":"R1427","DOI":"10.1152\/ajpregu.00479.2002","article-title":"Peptides that regulate food intake: Glucagon-like peptide 1-(7-36) amide acts at lateral and medial hypothalamic sites to suppress feeding in rats","volume":"284","author":"Schick","year":"2003","journal-title":"American Journal of Physiology - Regulatory, Integrative and Comparative Physiology"},{"key":"10.1016\/j.appet.2026.108723_bib109","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2147\/DMSO.S141235","article-title":"Reasons for discontinuation of GLP1 receptor agonists: Data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes","volume":"10","author":"Sikirica","year":"2017","journal-title":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy"},{"issue":"1","key":"10.1016\/j.appet.2026.108723_bib110","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s13578-022-00914-3","article-title":"Activation of arcuate nucleus glucagon-like peptide-1 receptor-expressing neurons suppresses food intake","volume":"12","author":"Singh","year":"2022","journal-title":"Cell & Bioscience"},{"key":"10.1016\/j.appet.2026.108723_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.appet.2022.106022","article-title":"A comparative transcriptomic analysis of glucagon-like peptide-1 receptor- and glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus","volume":"174","author":"Smith","year":"2022","journal-title":"Appetite"},{"issue":"6","key":"10.1016\/j.appet.2026.108723_bib112","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1053\/j.gastro.2007.09.005","article-title":"Glucose-dependent insulinotropic polypeptide enhances adipocyte development and glucose uptake in part through Akt activation","volume":"133","author":"Song","year":"2007","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.appet.2026.108723_bib113","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/ng.686","article-title":"Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index","volume":"42","author":"Speliotes","year":"2010","journal-title":"Nature Genetics"},{"issue":"8","key":"10.1016\/j.appet.2026.108723_bib114","doi-asserted-by":"crossref","first-page":"e1608","DOI":"10.1210\/clinem\/dgad734","article-title":"Obesity variants in the GIPR gene are not associated with risk of fracture or bone mineral density","volume":"109","author":"Styrkarsdottir","year":"2024","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"issue":"5","key":"10.1016\/j.appet.2026.108723_bib115","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.peptides.2011.02.011","article-title":"Sub-chronic administration of stable GIP analog in mice decreases serum LPL activity and body weight","volume":"32","author":"Szalowska","year":"2011","journal-title":"Peptides"},{"issue":"2","key":"10.1016\/j.appet.2026.108723_bib116","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1210\/clinem\/dgaa863","article-title":"Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes","volume":"106","author":"Thomas","year":"2021","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"issue":"3","key":"10.1016\/j.appet.2026.108723_bib117","doi-asserted-by":"crossref","first-page":"E224","DOI":"10.1152\/ajpendo.00347.2016","article-title":"Glucose-dependent insulinotropic polypeptide promotes lipid deposition in subcutaneous adipocytes in obese type 2 diabetes patients: A maladaptive response","volume":"312","author":"Thondam","year":"2017","journal-title":"American Journal of Physiology. Endocrinology and Metabolism"},{"issue":"1","key":"10.1016\/j.appet.2026.108723_bib118","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1152\/ajpendo.00100.2012","article-title":"Glucose-dependent insulinotropic polypeptide induces cytokine expression, lipolysis, and insulin resistance in human adipocytes","volume":"304","author":"Timper","year":"2013","journal-title":"American Journal of Physiology-Endocrinology and Metabolism"},{"issue":"6","key":"10.1016\/j.appet.2026.108723_bib119","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1210\/endo.133.6.8243312","article-title":"Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain","volume":"133","author":"Usdin","year":"1993","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.appet.2026.108723_bib120","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s42255-023-00966-w","article-title":"A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings","volume":"6","author":"V\u00e9niant","year":"2024","journal-title":"Nature Metabolism"},{"key":"10.1016\/j.appet.2026.108723_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101665","article-title":"Obesity medication lorcaserin activates brainstem GLP-1 neurons to reduce food intake and augments GLP-1 receptor agonist induced appetite suppression","volume":"68","author":"Wagner","year":"2023","journal-title":"Molecular Metabolism"},{"key":"10.1016\/j.appet.2026.108723_bib122","article-title":"Specific loss of GIPR signaling in GABAergic neurons enhances GLP-1R agonist-induced body weight loss","volume":"95","author":"Wean","year":"2024","journal-title":"Molecular Metabolism"},{"issue":"1","key":"10.1016\/j.appet.2026.108723_bib123","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/dom.14551","article-title":"Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss","volume":"24","author":"Wharton","year":"2022","journal-title":"Diabetes, Obesity and Metabolism"},{"issue":"11","key":"10.1016\/j.appet.2026.108723_bib124","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.appet.2026.108723_bib125","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.cell.2016.05.011","article-title":"Sensory neurons that detect stretch and nutrients in the digestive system","volume":"166","author":"Williams","year":"2016","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.appet.2026.108723_bib126","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.neuron.2008.09.033","article-title":"5-HT2CRs expressed by pro-opiomelanocortin neurons regulate energy homeostasis","volume":"60","author":"Xu","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.appet.2026.108723_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101638","article-title":"Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems","volume":"66","author":"Yang","year":"2022","journal-title":"Molecular Metabolism"},{"issue":"1","key":"10.1016\/j.appet.2026.108723_bib128","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.cmet.2024.11.003","article-title":"The GIP receptor activates futile calcium cycling in white adipose tissue to increase energy expenditure and drive weight loss in mice","volume":"37","author":"Yu","year":"2025","journal-title":"Cell Metabolism"},{"issue":"3","key":"10.1016\/j.appet.2026.108723_bib130","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.neuron.2020.11.010","article-title":"Area Postrema cell types that mediate nausea-associated behaviors","volume":"109","author":"Zhang","year":"2021","journal-title":"Neuron"},{"issue":"11","key":"10.1016\/j.appet.2026.108723_bib131","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110953","article-title":"A brainstem circuit for nausea suppression","volume":"39","author":"Zhang","year":"2022","journal-title":"Cell Reports"},{"issue":"4","key":"10.1016\/j.appet.2026.108723_bib129","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.cmet.2021.01.015","article-title":"The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling","volume":"33","author":"Zhang","year":"2021","journal-title":"Cell Metabolism"}],"container-title":["Appetite"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0195666326002850?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0195666326002850?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:26:48Z","timestamp":1788787608000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0195666326002850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":131,"alternative-id":["S0195666326002850"],"URL":"https:\/\/doi.org\/10.1016\/j.appet.2026.108723","relation":{},"ISSN":["0195-6663"],"issn-type":[{"value":"0195-6663","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"One receptor, two opposite approaches: efficacy and tolerability of GIPR agonism and antagonism in obesity pharmacotherapy","name":"articletitle","label":"Article Title"},{"value":"Appetite","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.appet.2026.108723","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108723"}}